SCHEMBL31664310

SCHEMBL31664310

Cc1cc(=O)n(C2CCCC2)c2nc(Nc3ccc4[nH]nnc4c3)ncc12

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 19/20 0.64
CCND1 P24385 19/20 0.64
CCND2 P30279 19/20 0.64
CCND3 P30281 19/20 0.64
NUAK1 O60285 2/20 0.63
FGFR1 P11362 1/20 0.63
FGFR2 P21802 1/20 0.63
FGFR4 P22455 1/20 0.63
FGFR3 P22607 1/20 0.63
MARK3 P27448 1/20 0.62
MARK2 Q7KZI7 1/20 0.62
MARK4 Q96L34 1/20 0.62
NUAK2 Q9H093 1/20 0.62
MARK1 Q9P0L2 1/20 0.62
CCNB2 O95067 1/20 0.62
CDK1 P06493 1/20 0.62
CCNB1 P14635 1/20 0.62
CCNB3 Q8WWL7 1/20 0.62
TTK P33981 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31664324 0.85 CDK4 (0.66) CDK4CCND1CCND2CCND3NUAK1
SCHEMBL6942977 0.85 CDK4 (0.66) CDK4CCND1CCND2CCND3NUAK1
SCHEMBL6808315 0.85 CDK4 (0.63) CDK4CCND1CCND2CCND3FGFR1
SCHEMBL31664316 0.85 CDK4 (0.67) CDK4CCND1CCND2CCND3NUAK1
SCHEMBL31664303 0.85 CDK4 (0.67) CDK4CCND1CCND2CCND3NUAK1
SCHEMBL6939861 0.84 CDK4 (0.66) CDK4CCND1CCND2CCND3NUAK1
SCHEMBL31664314 0.83 CDK4 (0.63) CDK4CCND1CCND2CCND3NUAK1
SCHEMBL6941988 0.83 CDK4 (0.65) CDK4CCND1CCND2CCND3NUAK1
SCHEMBL6938878 0.82 CDK4 (0.64) CDK4CCND1CCND2CCND3NUAK1
SCHEMBL31664317 0.81 CDK4 (0.63) CDK4CCND1CCND2CCND3NUAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388576-A1 PYRIDONOPYRIMIDINE DERIVATIVE AS RSK INHIBITOR AND USE THEREOF UNIV EAST CHINA NORMAL (CN) 2025-12-25 US disclosed
EP-4588917-A1 PYRIDONOPYRIMIDINE DERIVATIVE AS RSK INHIBITOR AND USE THEREOF East China Normal University (CN) 2025-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388576-A1 PYRIDONOPYRIMIDINE DERIVATIVE AS RSK INHIBITOR AND USE THEREOF RPS6KA1, RPS6KA3, RPS6KA5 CDK4 609/4885CCND1 2533/4885CCND2 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.